-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there are still few treatment options for disease progression during or after treatment with immune checkpoint inhibitors (ICI)
.
Existing data show that pembrolizumab and lenvatinib are effective as monotherapy in RCC , but the efficacy of the combination of these two drugs in the treatment of RCC patients is not clear
Immunization with pembrolizumab and levatinib as monotherapy is effective in RCC
This study aims to evaluate the safety of the efficacy of lenvatinib combined with pembrolizumab in patients with RCC
.
This article reports the results of a study evaluating the metastatic RCC cohort in a Phase 1b/2 open study of lenvatinib combined with pembrolizumab in patients with solid tumors
.
The test patients took 20 mg of lenvatinib orally every day, and intravenously infused 200 mg of pembrolizumab every 3 weeks until the disease progressed, intolerable toxicity appeared or the study was withdrawn
From July 21, 2015 to October 16, 2019, a total of 145 patients were recruited, of which 2 were non-clear cell RCC and were excluded from the efficacy analysis (1 in the initial treatment group and 1 in the ICI treated group); therefore , The curative effect analysis covers a total of 143 patients: 22 in the initial treatment group, 17 in the ICI initial treatment group, and 104 in the ICI treated group
.
All 145 patients were included in the safety analysis
Treatment remission in each subgroup
Treatment remission in each subgroupThe median follow-up was 19.
8 months (range 14.
3-28.
4)
.
At 24 weeks, 16 patients (72.
At 24 weeks, 16 patients (72.
PFS and OS in patients who have previously received ICI treatment with lenvatinib combined with pembrolizumab
PFS and OS in patients who have previously received ICI treatment with lenvatinib combined with pembrolizumabIn summary, lenvatinib combined with pembrolizumab has shown encouraging anti-tumor activity and controllable safety in patients with metastatic RCC who have previously received ICI therapy, and may be a good candidate for such patients.
Levatinib combined with pembrolizumab has shown encouraging anti-tumor activity and controllable safety in patients with metastatic RCC who have previously received ICI therapy, and may become a new choice for such patients
Original source:
Original source:Chung-Han Lee, et al.
Lenvatinib plus pembrolizumab in patients with either treatment -naive or previously treated metastatic renal cell carcinoma (Study 111 / KEYNOTE-146): a phase 1b / 2 study in this message
